Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
|Articles|July 30, 2021
- July 2021
- Volume 87
- Issue 7
July 2021 Interactives: Pet Peeves
Penny pinchers, early arrivals, and more are featured in this month's Pet Peeves.
Advertisement
Penny Pincher: Patient copay is $1 but they want you to try GoodRx.
Early Arrival: Patient asks for a transfer, you say 1 hour and they arrive in 15 minutes.
New Year, New Insurance: New year but "I have the same insurance" yet they did get a card in the mail...
What's bothering you? Bossy patients, abandoned prescriptions, drive-through demands? We want to know! Send your pet peeves to [email protected]. We'll share them here and in the publication.
Articles in this issue
about 5 years ago
OTC Product News: July 2021about 5 years ago
Rx Product News: July 2021about 5 years ago
Labeling and Packaging Issues Contribute to Dose, Quantity Errorsabout 5 years ago
Study: Women With CAD, Heart Disease Often Go Undertreatedabout 5 years ago
How Does the EUA for the COVID-19 Vaccines Work?about 5 years ago
Lifestyle Changes Can Improve Inflammatory Burdenabout 5 years ago
Patients With Epilepsy Are Skeptical About Generic Antiseizure Drugsabout 5 years ago
Training Program Helps Pharmacists Provide Diabetes Careabout 5 years ago
July 2021 Interactives: Case StudiesAdvertisement
Related to this article
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
4
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
5